Abstract: Metal effect pigments, having a surface treatment comprising A) phosphoric acid (H3PO4), B) tetraethyl orthosilicate (TEOS) and C) at least one organic coupling agent to the metal effect pigments, exhibiting excellent humidity resistance performance without any influence on the chroma, luster and color of base metal effect pigments, a process for producing same and their use.

Abstract: A layer, sheet or film containing one or more flake-form effect pigments and one or more light scattering centers, methods for its preparation, its use for any type of device collecting solar cell energy, including but not limited to coloring solar cells or solar cell modules, and devices collecting solar cell energy, including but not limited to colored solar cells or colored solar cell modules, comprising such a layer, sheet or film, and methods for their preparation.

Abstract: Liquid-crystalline (LC) media or LC materials and energy saving liquid-crystal displays (LCDs) containing these media, especially gaming displays and AR/VR headsets addressed by an active matrix and in particular to LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type.

Abstract: Metal complexes including cyclopentadienyl ligands and methods of using such metal complexes to prepare metal-containing films are provided.

Abstract: The disclosed subject matter relates compounds of structure (I), and polymers of structure (II) having a polydispersity ranging from 1 to about 1.1, compositions comprising said polymers and a spin casting solvent, the process of forming a pinning layer selectively on metal with said composition and the process of using said pinning layers to affect chemoepitaxy directed self-assembly of an overlying block copolymer, and the subsequent process of pattern transfer of this self-assembled layer into a substrate by etching.

Abstract: The present disclosure relates to new folate-conjugates comprising a 5-methyltetrahydro-folate, a radiometal chelator optionally coordinating a radiometal M, and the albumin binder 5-(p-iodophenyl)pentanoate, and further provides uses of such conjugates and/or pharmaceutical compositions thereof in diagnostic imaging, radionuclide therapy or theragnostic applications.

Abstract: The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.

Abstract: A stirring device for stirring a biphasic fluid has a stirring shaft that can be mounted with a mounting end into a stirring drive. The stirring device also has a first paddle that is arranged in a rotationally fixed manner at or near a stirring end of the stirring shaft that is opposite to the mounting end, and further has a second paddle that is arranged in a rotationally fixed manner at the stirring shaft in between the mounting end and the first paddle. The second paddle is mounted with respect to the stirring shaft in such a manner that it can be displaced in an axial direction along the stirring shaft, which allows for a change of an axial distance between the second paddle and the mounting end of the stirring shaft.

Abstract: Antibodies which bind human CEACAM5 protein, as well as isolated nucleic acids and host cells containing a sequence encoding said antibodies are disclosed. Immunoconjugates containing said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions containing antibodies or said immunoconjugates are also disclosed. A use of the antibodies, immunoconjugates, and pharmaceutical compositions disclosed herein is provided for the treatment of cancer or for diagnostic purposes.

Abstract: The present application relates to materials for use in electronic devices, to processes for preparing the materials, and to electronic devices containing the materials.

Abstract: The invention relates to fluorene derivatives and electronic devices, particularly organic electroluminescent devices in which said compounds are used, particularly as a matrix material for phosphorescent emitters.

Abstract: The present invention relates to resist compositions comprising a polymer component, a photoacid generator component (PAG), a photoactive diazonaphthoquinone component (PAC), a base component, a solvent component, and optionally, a heterocyclic thiol component. The polymer component is a Novolak derivative, comprising Novolak repeat units with free phenolic hydroxy moieties, and Novolak repeat units comprising phenolic hydroxy moieties protected with an acid cleavable acetal moiety.

Abstract: The present disclosure relates to new folate-conjugates comprising a 5-methyltetrahydrofolate, a radiometal chelator optionally coordinating a radiometal M, and an albumin binder linked through a hydrophobic linker, and further provides uses of such conjugates and/or pharmaceutical compositions thereof in diagnostic imaging, radionuclide therapy or theragnostic applications.

Abstract: The present invention relates to an LC medium comprising two or more polymerizable compounds, at least one of which contains a substituent comprising a tertiary OH group, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the PSA (polymer sustained alignment) or SA (self-aligning) mode, to an LC display of the PSA or SA mode comprising the LC medium, and to a process of manufacturing the LC display using the LC medium, especially an energy-saving LC display and energy-saving LC display production process.

Abstract: An optical component is described which contains a liquid crystal (LC) medium, operable in the infrared region of the electromagnetic spectrum. The LC medium, which can be used in the infrared (IR) region, can contain one or more compounds of the formulae I, II, and III in which the occurring groups and parameters have the meanings defined herein, and preferably contain one or more compounds of the formula RO in which the occurring groups and parameters have the meanings defined herein.

Abstract: The present invention relates to a liquid crystal (LC) medium comprising a compound of formula I and one or more compounds selected from the group of compounds of the formulae IIA, IIB, IIC and IID, as defined in claim 1, and to the use thereof for optical, electro-optical and electronic purposes, in particular in LC displays, especially in IPS, FFS, VA or PS-VA displays.

Abstract: Methods, compositions, and medical kits are useful for treating and preventing multiple sclerosis using 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one, or a pharmaceutically acceptable salt thereof, according to preferred dosing regimens.

Abstract: An atomic layer etching method using a ligand exchange reaction may include a substrate providing step of putting a substrate with a thin film formed thereon into a reaction chamber, a halogenated thin film forming step of forming a halogenated thin film on a surface of the thin film by infusing a halogenated gas into the reaction chamber, and an etching step of etching the halogenated thin film by infusing a ligand without a metal or metal precursor into the reaction chamber with the substrate with the halogenated thin film.

Abstract: A liquid crystal device for absorbing and/or scattering a controllable amount of traversing light comprises an active layer having a first viewport surface, a second viewport surface, and at least two side surfaces. The first and second viewport surfaces contact respective first and second planar electrodes. The first and second planar electrodes respectively comprise first and second supply areas for receiving a control voltage for controlling the active layer. A first supply contacting device electrically connects to the first supply area, and a second supply contacting device electrically connects to the second supply area. The supply areas and the supply contacting devices each associate to one or more side surfaces, arranged to extend along at least a part of their respective associated sides, wherein the first supply contacting device and the second supply contacting device associate to adjacent side surfaces.

Abstract: The invention relates to substituted heterocycles of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.